Evidence map›Paper›PMID 26233684›Full record

ArticleEndocrine2016

Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study.

Marcos M Lima-Martínez, Mariela Paoli, Marianela Rodney, Nathalie Balladares, Miguel Contreras, Luis D'Marco, Gianluca Iacobellis

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Diabetes and cancer: therapeutic implications.Cardio-oncology (London, England) · 2026
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Marcos M Lima-MartínezDepartamento de Ciencias Fisiológicas, Universidad de Oriente, Núcleo Bolívar, Ciudad Bolívar, Venezuela. marcoslimamedical@hotmail.com.
Mariela PaoliInstituto Autónomo Hospital Universitario de los Andes, Unidad de Endocrinología, Mérida, Venezuela.
Marianela RodneyServicio de Cardiología, Hospital Universitario Ruíz y Páez, Ciudad Bolívar, Venezuela.
Nathalie BalladaresDepartamento de Ciencias Fisiológicas, Universidad de Oriente, Núcleo Bolívar, Ciudad Bolívar, Venezuela.
Miguel ContrerasCentro Médico El Valle, Nueva Esparta, Venezuela.
Luis D'MarcoClínica Puerto Ordaz, Unidad Avanzada de Investigación y Diagnóstico Ecográfico y Renal (UNIRENAL), Ciudad Guayana, Venezuela.
Gianluca IacobellisDivision of Endocrinology, Department of Medicine, University of Miami Miller School of Medicine, Miami, USA.
Universidad de Oriente · VEUniversidad Nacional Experimental de Guayana · VEUniversity of Miami · USUniversity of the Andes · VE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study was to assess the effect of sitagliptin addition on the epicardial adipose tissue (EAT) thickness in subjects with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. This was a 24-week interventional pilot study in 26 consecutive type 2 diabetic patients, 14 females and 12 males average age of 43.8 ± 9.0 years, with Hemoglobin A1c (HbA1c) ≥ 7% on metformin monotherapy. Subjects who met the inclusion criteria were added on sitagliptin and started on sitagliptin/metformin combination at the dosage of 50 mg/1000 mg twice daily. EAT and visceral and total body fat were measured, respectively, with echocardiography and bioelectrical impedance analysis at baseline and after 24 weeks of sitagliptin/metformin treatment in each subject. HbA1c and plasma lipids were also measured. EAT decreased significantly from 9.98 ± 2.63 to 8.10 ± 2.11 mm, p = 0.001, accounting for a percentage of reduction (∆%) of -15% after 24 weeks of sitagliptin addition, whereas total body fat percentage, visceral fat, and body mass index (BMI), decreased by 8, 12, and 7%, respectively (p = 0.001 for all). After 6 month, EAT ∆% was significantly correlated with ∆% of visceral fat (r = 0.456; p = 0.01), whereas no correlation with either BMI ∆% (r = 0.292; p = 0.147) or HbA1c ∆% was found. The addition of Sitagliptin produced a significant and rapid reduction of EAT, marker of organ-specific visceral fat, in overweight/obese individuals with type 2 diabetes inadequately controlled on metformin monotherapy. EAT as measured with ultrasound can serve as no invasive and accurate marker of visceral fat changes during pharmaceutical interventions targeting the fat.

Indexed as

Adipose TissueAdiposityAdolescentAdultAgedBody CompositionDiabetes Mellitus, Type 2Drug Therapy, CombinationElectric ImpedanceFemaleGlycated HemoglobinHumansHypoglycemic AgentsLipidsMaleMetforminGlycated HemoglobinHypoglycemic AgentsLipidsMetforminSitagliptin PhosphateDietEpicardial adipose tissueEpicardial fatExerciseSitagliptin

Identifiers

PMID26233684
OpenAlexW948379226

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.